PubMed:24603724 JSONTXT

{"project":"PubMed_ArguminSci","denotations":[{"id":"T1","span":{"begin":147,"end":325},"obj":"DRI_Approach"},{"id":"T2","span":{"begin":326,"end":536},"obj":"DRI_Outcome"},{"id":"T3","span":{"begin":537,"end":628},"obj":"DRI_Background"},{"id":"T4","span":{"begin":629,"end":857},"obj":"DRI_Approach"},{"id":"T5","span":{"begin":858,"end":1010},"obj":"DRI_Outcome"},{"id":"T6","span":{"begin":1011,"end":1130},"obj":"DRI_Approach"},{"id":"T7","span":{"begin":1131,"end":1390},"obj":"DRI_Approach"},{"id":"T8","span":{"begin":1391,"end":1523},"obj":"DRI_Challenge"},{"id":"T9","span":{"begin":1524,"end":1677},"obj":"DRI_Outcome"}],"text":"TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.\nNeuroblastoma (NB) is the most common extra-cranial pediatric solid tumor with up to 50% of NB patients classified as having high-risk disease with poor long-term survival rates. The poor clinical outcome and aggressiveness of high-risk NB strongly correlates with enhanced angiogenesis, suggesting anti-angiogenic agents as attractive additions to the currently insufficient therapeutics. TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis. In the current study, we used the SK-N-BE (2) cell line to generate orthotopic NB tumors in order to study the combinational therapeutic potential of TL-118 with either Gemcitabine (40 mg/kg; IP) or Retinoic acid (40 mg/kg; IP). We show that TL-118 treatment (n = 9) significantly inhibited tumor growth, increased cell apoptosis, reduced proliferation and extended mouse survival. Moreover, the reciprocal effect of TL-118 and Gemcitabine treatment (n = 10) demonstrated improved anti-tumor activity. The synergistic effect of these drugs in combination was more effective than either TL or Gemcitabine alone (n = 9), via significantly reduced cell proliferation (p\u003c0.005), increased apoptosis (p\u003c0.05) and significantly prolonged survival (2-fold; p\u003c0.00001). To conclude, we demonstrate that the novel drug combination TL-118 has the ability to suppress the growth of an aggressive NB tumor. The promising results with TL-118 in this aggressive animal model may imply that this drug combination has therapeutic potential in the clinical setting."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":146},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":147,"end":325},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":326,"end":536},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":537,"end":628},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":629,"end":857},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":858,"end":1010},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":1011,"end":1130},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1131,"end":1390},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":1391,"end":1523},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":1524,"end":1677},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":146},"obj":"Sentence"},{"id":"T2","span":{"begin":147,"end":325},"obj":"Sentence"},{"id":"T3","span":{"begin":326,"end":536},"obj":"Sentence"},{"id":"T4","span":{"begin":537,"end":628},"obj":"Sentence"},{"id":"T5","span":{"begin":629,"end":857},"obj":"Sentence"},{"id":"T6","span":{"begin":858,"end":1010},"obj":"Sentence"},{"id":"T7","span":{"begin":1011,"end":1130},"obj":"Sentence"},{"id":"T8","span":{"begin":1131,"end":1390},"obj":"Sentence"},{"id":"T9","span":{"begin":1391,"end":1523},"obj":"Sentence"},{"id":"T10","span":{"begin":1524,"end":1677},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.\nNeuroblastoma (NB) is the most common extra-cranial pediatric solid tumor with up to 50% of NB patients classified as having high-risk disease with poor long-term survival rates. The poor clinical outcome and aggressiveness of high-risk NB strongly correlates with enhanced angiogenesis, suggesting anti-angiogenic agents as attractive additions to the currently insufficient therapeutics. TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis. In the current study, we used the SK-N-BE (2) cell line to generate orthotopic NB tumors in order to study the combinational therapeutic potential of TL-118 with either Gemcitabine (40 mg/kg; IP) or Retinoic acid (40 mg/kg; IP). We show that TL-118 treatment (n = 9) significantly inhibited tumor growth, increased cell apoptosis, reduced proliferation and extended mouse survival. Moreover, the reciprocal effect of TL-118 and Gemcitabine treatment (n = 10) demonstrated improved anti-tumor activity. The synergistic effect of these drugs in combination was more effective than either TL or Gemcitabine alone (n = 9), via significantly reduced cell proliferation (p\u003c0.005), increased apoptosis (p\u003c0.05) and significantly prolonged survival (2-fold; p\u003c0.00001). To conclude, we demonstrate that the novel drug combination TL-118 has the ability to suppress the growth of an aggressive NB tumor. The promising results with TL-118 in this aggressive animal model may imply that this drug combination has therapeutic potential in the clinical setting."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":74,"end":78},"obj":"gene:4613"},{"id":"T1","span":{"begin":100,"end":113},"obj":"disease:C0027819"},{"id":"T2","span":{"begin":74,"end":78},"obj":"gene:4613"},{"id":"T3","span":{"begin":100,"end":113},"obj":"disease:C0700095"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.\nNeuroblastoma (NB) is the most common extra-cranial pediatric solid tumor with up to 50% of NB patients classified as having high-risk disease with poor long-term survival rates. The poor clinical outcome and aggressiveness of high-risk NB strongly correlates with enhanced angiogenesis, suggesting anti-angiogenic agents as attractive additions to the currently insufficient therapeutics. TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis. In the current study, we used the SK-N-BE (2) cell line to generate orthotopic NB tumors in order to study the combinational therapeutic potential of TL-118 with either Gemcitabine (40 mg/kg; IP) or Retinoic acid (40 mg/kg; IP). We show that TL-118 treatment (n = 9) significantly inhibited tumor growth, increased cell apoptosis, reduced proliferation and extended mouse survival. Moreover, the reciprocal effect of TL-118 and Gemcitabine treatment (n = 10) demonstrated improved anti-tumor activity. The synergistic effect of these drugs in combination was more effective than either TL or Gemcitabine alone (n = 9), via significantly reduced cell proliferation (p\u003c0.005), increased apoptosis (p\u003c0.05) and significantly prolonged survival (2-fold; p\u003c0.00001). To conclude, we demonstrate that the novel drug combination TL-118 has the ability to suppress the growth of an aggressive NB tumor. The promising results with TL-118 in this aggressive animal model may imply that this drug combination has therapeutic potential in the clinical setting."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":147,"end":160},"obj":"HP_0003006"},{"id":"T2","span":{"begin":215,"end":220},"obj":"HP_0002664"},{"id":"T3","span":{"begin":356,"end":370},"obj":"HP_0000718"},{"id":"T4","span":{"begin":609,"end":614},"obj":"HP_0002664"},{"id":"T5","span":{"begin":711,"end":717},"obj":"HP_0002664"},{"id":"T6","span":{"begin":920,"end":925},"obj":"HP_0002664"},{"id":"T7","span":{"begin":1115,"end":1120},"obj":"HP_0002664"},{"id":"T8","span":{"begin":1503,"end":1513},"obj":"HP_0000718"},{"id":"T9","span":{"begin":1517,"end":1522},"obj":"HP_0002664"},{"id":"T10","span":{"begin":1566,"end":1576},"obj":"HP_0000718"}],"text":"TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.\nNeuroblastoma (NB) is the most common extra-cranial pediatric solid tumor with up to 50% of NB patients classified as having high-risk disease with poor long-term survival rates. The poor clinical outcome and aggressiveness of high-risk NB strongly correlates with enhanced angiogenesis, suggesting anti-angiogenic agents as attractive additions to the currently insufficient therapeutics. TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis. In the current study, we used the SK-N-BE (2) cell line to generate orthotopic NB tumors in order to study the combinational therapeutic potential of TL-118 with either Gemcitabine (40 mg/kg; IP) or Retinoic acid (40 mg/kg; IP). We show that TL-118 treatment (n = 9) significantly inhibited tumor growth, increased cell apoptosis, reduced proliferation and extended mouse survival. Moreover, the reciprocal effect of TL-118 and Gemcitabine treatment (n = 10) demonstrated improved anti-tumor activity. The synergistic effect of these drugs in combination was more effective than either TL or Gemcitabine alone (n = 9), via significantly reduced cell proliferation (p\u003c0.005), increased apoptosis (p\u003c0.05) and significantly prolonged survival (2-fold; p\u003c0.00001). To conclude, we demonstrate that the novel drug combination TL-118 has the ability to suppress the growth of an aggressive NB tumor. The promising results with TL-118 in this aggressive animal model may imply that this drug combination has therapeutic potential in the clinical setting."}

{"project":"Allie","denotations":[{"id":"SS1_24603724_1_0","span":{"begin":147,"end":160},"obj":"expanded"},{"id":"SS2_24603724_1_0","span":{"begin":162,"end":164},"obj":"abbr"}],"relations":[{"id":"AE1_24603724_1_0","pred":"abbreviatedTo","subj":"SS1_24603724_1_0","obj":"SS2_24603724_1_0"}],"text":"TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.\nNeuroblastoma (NB) is the most common extra-cranial pediatric solid tumor with up to 50% of NB patients classified as having high-risk disease with poor long-term survival rates. The poor clinical outcome and aggressiveness of high-risk NB strongly correlates with enhanced angiogenesis, suggesting anti-angiogenic agents as attractive additions to the currently insufficient therapeutics. TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis. In the current study, we used the SK-N-BE (2) cell line to generate orthotopic NB tumors in order to study the combinational therapeutic potential of TL-118 with either Gemcitabine (40 mg/kg; IP) or Retinoic acid (40 mg/kg; IP). We show that TL-118 treatment (n = 9) significantly inhibited tumor growth, increased cell apoptosis, reduced proliferation and extended mouse survival. Moreover, the reciprocal effect of TL-118 and Gemcitabine treatment (n = 10) demonstrated improved anti-tumor activity. The synergistic effect of these drugs in combination was more effective than either TL or Gemcitabine alone (n = 9), via significantly reduced cell proliferation (p\u003c0.005), increased apoptosis (p\u003c0.05) and significantly prolonged survival (2-fold; p\u003c0.00001). To conclude, we demonstrate that the novel drug combination TL-118 has the ability to suppress the growth of an aggressive NB tumor. The promising results with TL-118 in this aggressive animal model may imply that this drug combination has therapeutic potential in the clinical setting."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"24603724-0#74#78#gene4613","span":{"begin":74,"end":78},"obj":"gene4613"},{"id":"24603724-0#100#113#diseaseC0027819","span":{"begin":100,"end":113},"obj":"diseaseC0027819"},{"id":"24603724-0#100#113#diseaseC0700095","span":{"begin":100,"end":113},"obj":"diseaseC0700095"}],"relations":[{"id":"74#78#gene4613100#113#diseaseC0027819","pred":"associated_with","subj":"24603724-0#74#78#gene4613","obj":"24603724-0#100#113#diseaseC0027819"},{"id":"74#78#gene4613100#113#diseaseC0700095","pred":"associated_with","subj":"24603724-0#74#78#gene4613","obj":"24603724-0#100#113#diseaseC0700095"}],"text":"TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.\nNeuroblastoma (NB) is the most common extra-cranial pediatric solid tumor with up to 50% of NB patients classified as having high-risk disease with poor long-term survival rates. The poor clinical outcome and aggressiveness of high-risk NB strongly correlates with enhanced angiogenesis, suggesting anti-angiogenic agents as attractive additions to the currently insufficient therapeutics. TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis. In the current study, we used the SK-N-BE (2) cell line to generate orthotopic NB tumors in order to study the combinational therapeutic potential of TL-118 with either Gemcitabine (40 mg/kg; IP) or Retinoic acid (40 mg/kg; IP). We show that TL-118 treatment (n = 9) significantly inhibited tumor growth, increased cell apoptosis, reduced proliferation and extended mouse survival. Moreover, the reciprocal effect of TL-118 and Gemcitabine treatment (n = 10) demonstrated improved anti-tumor activity. The synergistic effect of these drugs in combination was more effective than either TL or Gemcitabine alone (n = 9), via significantly reduced cell proliferation (p\u003c0.005), increased apoptosis (p\u003c0.05) and significantly prolonged survival (2-fold; p\u003c0.00001). To conclude, we demonstrate that the novel drug combination TL-118 has the ability to suppress the growth of an aggressive NB tumor. The promising results with TL-118 in this aggressive animal model may imply that this drug combination has therapeutic potential in the clinical setting."}

{"project":"DisGeNet-2017-sample","denotations":[{"id":"T40","span":{"begin":74,"end":78},"obj":"gene:4613"},{"id":"T41","span":{"begin":100,"end":113},"obj":"disease:C0027819"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T40","obj":"T41"},{"id":"R2","pred":"associated_with","subj":"T40","obj":"T41"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.\nNeuroblastoma (NB) is the most common extra-cranial pediatric solid tumor with up to 50% of NB patients classified as having high-risk disease with poor long-term survival rates. The poor clinical outcome and aggressiveness of high-risk NB strongly correlates with enhanced angiogenesis, suggesting anti-angiogenic agents as attractive additions to the currently insufficient therapeutics. TL-118, a novel drug combination has been recently developed to inhibit tumor angiogenesis. In the current study, we used the SK-N-BE (2) cell line to generate orthotopic NB tumors in order to study the combinational therapeutic potential of TL-118 with either Gemcitabine (40 mg/kg; IP) or Retinoic acid (40 mg/kg; IP). We show that TL-118 treatment (n = 9) significantly inhibited tumor growth, increased cell apoptosis, reduced proliferation and extended mouse survival. Moreover, the reciprocal effect of TL-118 and Gemcitabine treatment (n = 10) demonstrated improved anti-tumor activity. The synergistic effect of these drugs in combination was more effective than either TL or Gemcitabine alone (n = 9), via significantly reduced cell proliferation (p\u003c0.005), increased apoptosis (p\u003c0.05) and significantly prolonged survival (2-fold; p\u003c0.00001). To conclude, we demonstrate that the novel drug combination TL-118 has the ability to suppress the growth of an aggressive NB tumor. The promising results with TL-118 in this aggressive animal model may imply that this drug combination has therapeutic potential in the clinical setting."}